Literature DB >> 12478109

Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression.

I Iborra1, E Solsona, J Casanova, J V Ricós, J Rubio, M A Climent.   

Abstract

PURPOSE: We evaluate the safety and efficacy of conservative elective treatment of upper urinary tract tumors, and determine predictive factors for recurrence and progression to optimize indications of this type of treatment.
MATERIALS AND METHODS: Since 1984 we have performed a prospective study of conservative treatment of single, low grade and stage, less than 3 cm. upper tract tumors. The study includes 54 patients with a normal contralateral kidney who had been followed for more than 36 months. Open conservative surgery was performed in 31 cases and endourological surgery in 23. Minimum followup was 36 months, maximum 210 and mean 84.8. Univariate and multivariate analyses of recurrence and progression were performed in relation to age, sex, association with a bladder tumor, bladder tumor stage and grade, sequence of bladder tumor in relation to upper urinary tract tumor, number of previous bladder tumor recurrences, association with bladder carcinoma in situ, upper urinary tract tumor grade, stage, location, size and therapy, and upper urinary tract cytology.
RESULTS: Of the 54 patients 19 (35%) had recurrence, which was bilateral recurrence in 4, and progression occurred in 9 (16%). At the end of analysis 44 (62.9%) patients were disease-free and alive at a mean time of 92.88 months, 13 (24%) died disease-free at a mean of 72.7 months and 7 (12.9%) died of disease at a mean of 97.85 months. Cause specific mortality occurred in 7 (12.9% cases). Among the 54 initially conservatively treated units 42 (77.7%) kidneys were ultimately preserved. On univariate and multivariate analysis tumor location in the renal pelvis and association with a previous multi-recurrent bladder tumor were variables significantly related to recurrence and progression, as well as bilateral recurrence.
CONCLUSIONS: Conservative treatment is an optional approach for select upper urinary tract tumors. The strongest risk factors for recurrence and progression were association with a previous multi-recurrent bladder tumor and tumor location in the renal pelvis but these conditions were also the strongest risk factors for bilateral recurrence. Conservative treatment can also be recommended in these cases but only with compliant patients and close followup.

Entities:  

Mesh:

Year:  2003        PMID: 12478109     DOI: 10.1097/01.ju.0000040589.56827.4a

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  Oncological and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Tomonori Kato; Ryo Nakayama; Tomomi Haba; Makoto Kawaguchi; Akira Komiya; Hiroshi Koike
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

Review 3.  Nephron-sparing Management of Upper Tract Urothelial Carcinoma.

Authors:  Francesca Suriano; Tommaso Brancato
Journal:  Rev Urol       Date:  2014

4.  Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma.

Authors:  Jay Simhan; Marc C Smaldone; Brian L Egleston; Daniel Canter; Steven N Sterious; Anthony T Corcoran; Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

5.  Conservative treatment of upper urinary tract carcinoma: Long-term results.

Authors:  Andrea Orosa Andrada; Inés Laso García; Fernando Arias Fúnez; Francisco Donis Canet; Gemma Duque Ruiz; Victoria Gómez Dos Santos; Francisco Javier Burgos Revilla
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

6.  Factors affecting the survival of patients treated by standard nephroureterectomy for transitional cell carcinoma of the upper urinary tract.

Authors:  Suleyman Ataus; Bulent Onal; Burcin Tunc; Ahmet Erozenci; Arman Cekmen; Ali Riza Kural; Armagan Oner
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 7.  Upper tract urothelial carcinoma: Paradigm shift towards nephron sparing management.

Authors:  Julia V Fiuk; Brad F Schwartz
Journal:  World J Nephrol       Date:  2016-03-06

Review 8.  Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma.

Authors:  Rao S Mandalapu; Mesut Remzi; Theo M de Reijke; Vitaly Margulis; J Palou; A Kapoor; Ofer Yossepowitch; Jonathan Coleman; Olivier Traxer; J Kyle Anderson; James Catto; Jean de la Rosette; Timothy O'Brien; Anthony Zlotta; Surena F Matin
Journal:  World J Urol       Date:  2016-05-27       Impact factor: 4.226

Review 9.  Results and outcomes after endoscopic treatment of upper urinary tract carcinoma: the Austrian experience.

Authors:  Harun Fajkovic; Tobias Klatte; Udo Nagele; Michael Dunzinger; Richard Zigeuner; Wilhelm Hübner; Mesut Remzi
Journal:  World J Urol       Date:  2012-09-27       Impact factor: 4.226

10.  Endoscopic management of upper tract urothelial carcinoma.

Authors:  K Moore; J Khastgir; M Ghei
Journal:  Adv Urol       Date:  2009-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.